甲状腺癌中caveolin-1与EGFR的逆向表达及其与BRAF V600E的联合价值
该研究在186例甲状腺细针穿刺(FNA)样本中检测caveolin-1免疫细胞化学表达、BRAF V600E突变及EGFR mRNA表达。结果发现EGFR上调见于恶性诊断、caveolin-1无表达且BRAF野生型组,EGFR与caveolin-1呈显著负相关;高caveolin-1/低EGFR病例与更晚pT分期及更高度肿瘤浸润相关,提示联合caveolin-1、BRAF V600E与EGFR或有助于FNA中识别更具侵袭性的甲状腺病变。
要点
- FNA样本中caveolin-1表达缺失与BRAF V600E突变均与恶性诊断一致。
- EGFR与caveolin-1表达呈显著负相关,双免疫荧光证实共定位与逆向表达。
- EGFR过表达与恶性相关但不与肿瘤侵袭性相关;高caveolin-1/低EGFR与更晚pT及更高浸润相关。
核心结论
- EGFR过表达与甲状腺恶性相关但不与肿瘤侵袭性相关。
- 高caveolin-1/低EGFR病例比低caveolin-1/高EGFR病例pT分期更晚、肿瘤浸润程度更高。
- 联合caveolin-1、BRAF V600E与EGFR可能有助于在FNA样本中从相对惰性肿瘤中识别更具侵袭性的甲状腺病变,用于早期风险分层。
研究设计与样本
- 研究纳入FNA活检样本n=186,检测caveolin-1免疫细胞化学表达与BRAF V600E突变。
- 按最终组织病理诊断、caveolin-1表达和BRAF V600E突变状态分组后测量EGFR mRNA表达。
- 采用Spearman秩相关分析EGFR与caveolin-1的相关性,并用双免疫荧光验证共定位与逆向表达。
主要发现
- FNA样本中caveolin-1免疫细胞化学表达与BRAF V600E突变均与恶性一致。
- EGFR上调见于恶性诊断、无caveolin-1表达且BRAF野生型的患者组。
- Spearman秩相关显示EGFR与caveolin-1呈统计学显著负相关。
- 双免疫荧光证实EGFR与caveolin-1共定位且逆向表达。
- 高caveolin-1/低EGFR病例与更晚pT分期及更高度肿瘤浸润相关。
临床怎么用
- 在甲状腺结节FNA评估中,可结合caveolin-1免疫细胞化学与BRAF V600E突变检测辅助恶性判断。
- 对caveolin-1与EGFR表达进行联合解读,高caveolin-1/低EGFR模式提示需关注更晚pT与更高浸润风险。
- 将caveolin-1、BRAF V600E与EGFR联合分析或有助于甲状腺癌患者的早期风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytological analysis of fine-needle aspiration (FNA) is the first step in evaluation of patients with nodular thyroid disease with the primary goal to exclude thyroid malignancy. Its improvement by combining cytology with molecular markers is still a matter of investigation. In this study, 2 molecular markers were used: caveolin-1 and epidermal growth factor receptor (EGFR), along with the well-established genetic marker BRAF V600E mutation. We set out to determine the expression signatures of EGFR and caveolin-1 in patients with thyroid malignancy as well as to determine their possible association with disease severity. In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy. The patients were sorted according to 3 parameters: final histopathological diagnosis, caveolin-1 expression, and BRAF V600E mutation status before measurement of EGFR mRNA expression. EGFR upregulation was detected in the group of patients with malignant diagnosis, no caveolin-1 expression, and wild-type BRAF. Spearman rank correlation yielded a statistically significant negative correlation of EGFR and caveolin-1. Double immunofluorescence confirmed colocalization and inverse expression of EGFR and caveolin-1. Our data demonstrated that EGFR overexpression is associated with malignancy but not with tumor aggressiveness. Furthermore, high-caveolin-1/low-EGFR cases were associated with an advanced pT status and had a greater degree of neoplastic infiltration than low-caveolin-1/high-EGFR cases. Combining caveolin-1 and BRAF V600E with EGFR might help in recognizing more aggressive thyroid lesions in a pool of relatively indolent tumors in FNA biopsies and thus be useful for early risk stratification of thyroid cancer patients.
引用
- Janković J, Tatić S, Božić V, et al. Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. Hum Pathol. 2016. PMID: 27818286. doi:10.1016/j.humpath.2016.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。